New frontline attack on leukemia: CAR-T cells join chemo to boost survival
NCT ID NCT06481241
Summary
This study is testing whether adding a type of immunotherapy called CAR-T cell therapy to standard chemotherapy can better control a type of adult blood cancer (B-cell acute lymphoblastic leukemia). The goal is to see if this combination leads to longer survival with fewer relapses and less severe side effects compared to chemotherapy alone. Researchers will give CAR-T cells to patients who have already achieved remission with initial chemotherapy, aiming to deepen that remission and prevent the cancer from returning.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PHILADELPHIA CHROMOSOME NEGATIVE ALL are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Institute of Hematology & Blood Diseases Hospital
RECRUITINGTianjin, 300020, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.